About Century Therapeutics, Inc. (IPSC): stock profile, AI score and financials
Century Therapeutics, Inc. (IPSC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IPSC at 31.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,452 of 2,925 stocks — the bottom half of the AI-ranked universe. IPSC scores in the top quartile across institutional flow (92.1), revenue growth (85.3). Areas of concern include revenue scale (1.4) and free cash flow (1.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 21.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Century Therapeutics, Inc. reports net income of $-34.5M, free cash flow of $-20.5M. Top institutional holders of IPSC by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management, Versant Venture Management, based on the most recent SEC filings. IPSC trades on the Nasdaq exchange and files with the SEC under CIK 1850119. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IPSC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Century Therapeutics, Inc. directly from SEC EDGAR.